LDHA and Alzheimer disease: Small-molecule LDHA inhibitors such as oxamate and FX11 show therapeutic promise across vascular disease models: they can reverse Aortic dissection (AD) pathology, reduce lesion severity and increase survival in AD mouse models [106], as well as promote extracellular mitochondrial and ATP release to mediate neuroprotection [119,121].